Novel pathogenetic mechanisms and therapeutic targets in B cell lymphomas

Published: June 8, 2009
Abstract Views: 138
PDF: 155
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

B cell derived Non-Hodgkin Lymphoma (B-NHL), including Burkitt lymphoma (BL and diffuse large B cell lymphoma (DLBCL) developing in children, represent a heterogeneous group of malignancies that arise by malignant transformation of B cells within the germinal center (GC). Within GC, antigen-stimulated B cells undergo rapid proliferation and specific genome remodeling processes such as Immunoglobulin (Ig) somatic hypermutation (SHM), and class switch recombination (CSR).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Dalla-Favera, R. (2009). Novel pathogenetic mechanisms and therapeutic targets in B cell lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.398